Safety

[키워드] 1:1 ABO blood type Acute coronary syndrome administration Adverse reaction Adverse reactions aliquot Aliquots All participants allocation anaphylaxis antibody Antigen assessment Bilirubin Blinding block blocks blood gas blood gas analysis blood type C-reactive protein calculated Capacity carried case report form clinical clinical trial clinical trials Coagulation Coma completion confidence level congestive heart failure contraindication control group convalescent plasma coronary syndrome COVID-19 COVID-19 disease COVID-19 pneumonia creatinine Critical Critical disease CRP current D-dimer decrease defined detect Diagnosis dialysis disease Disseminated intravascular coagulation dissemination Donor donors drop Duration Dynamics eCRF Efficacy electronic case report form element eligible enrolled enrolment etiology evaluate evaluated events Evolution exclusion criteria expected experimental group exploratory failure following gas analysis hemodynamic instability hemorrhage hospital hospital discharge Hospitalization Hospitalized hospitalized patient hospitalized patients Hypothesis Hypoxemia ICU IIb in-hospital mortality Inclusion Infarction Inflammatory information Informed consent intensive care intensive care unit Intervention intracranial hemorrhage intravascular coagulation Invasive mechanical ventilation investigator investigators jaundice Laboratory laboratory confirmation Laboratory test Lactate lactate dehydrogenase Length less Local lymphocyte male marker Mechanical mechanical ventilation mmHg molecular Mortality multi-organ failure Myocardial infarction Neutralizing antibodies number objective occur Older open open label outcome oxygen Oxygen requirement oxygen saturation PaO participant Patient performed plasma Platelets Pneumonia power power of 80% previous diagnosis Probability protocol Public Hospital public hospitals quantification randomization Randomized Randomized controlled trial rationale receive reduce reducing reduction Registered resolution of symptom respiratory respiratory rate routine clinical practice Safe Safety Sample size SARS-COV-2 infection score Secondary objectives serious adverse reaction Serious adverse reactions serologic serum serum creatinine severe COVID-19 Severe COVID-19 pneumonia severe disease SOFA specific type standard treatment standard treatment alone statistical analysis Study protocol Stupor subject supplementary material Total total bilirubin transfusion treatment arm Trial uncontrolled vasopressors Ventilation website with COVID-19
[DOI] 10.1186/s13063-021-05189-6 PMC 바로가기 [Article Type] Letter